HK1249857A1 - 片劑 - Google Patents

片劑

Info

Publication number
HK1249857A1
HK1249857A1 HK18109337.3A HK18109337A HK1249857A1 HK 1249857 A1 HK1249857 A1 HK 1249857A1 HK 18109337 A HK18109337 A HK 18109337A HK 1249857 A1 HK1249857 A1 HK 1249857A1
Authority
HK
Hong Kong
Prior art keywords
tablet
Prior art date
Application number
HK18109337.3A
Other languages
English (en)
Inventor
Arisa Maeda
Yuichi Sugiyama
Yoshihiro Uchiyama
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of HK1249857A1 publication Critical patent/HK1249857A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
HK18109337.3A 2015-07-30 2018-07-19 片劑 HK1249857A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015151336 2015-07-30
PCT/JP2016/072109 WO2017018473A1 (ja) 2015-07-30 2016-07-28 錠剤

Publications (1)

Publication Number Publication Date
HK1249857A1 true HK1249857A1 (zh) 2018-11-16

Family

ID=57884505

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18109337.3A HK1249857A1 (zh) 2015-07-30 2018-07-19 片劑

Country Status (19)

Country Link
US (1) US10835541B2 (zh)
EP (1) EP3329921B1 (zh)
JP (1) JP6778680B2 (zh)
KR (1) KR20180030412A (zh)
CN (1) CN108135915B (zh)
BR (1) BR112018001859B1 (zh)
CA (1) CA2994073C (zh)
CL (1) CL2018000246A1 (zh)
CO (1) CO2018000991A2 (zh)
CR (1) CR20180119A (zh)
EC (1) ECSP18015616A (zh)
HK (1) HK1249857A1 (zh)
MX (1) MX2018001209A (zh)
MY (1) MY189306A (zh)
PE (1) PE20180605A1 (zh)
PH (1) PH12018500236A1 (zh)
SG (2) SG11201800591TA (zh)
TW (1) TWI710379B (zh)
WO (1) WO2017018473A1 (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019013310A1 (en) * 2017-07-10 2019-01-17 Takeda Pharmaceutical Company Limited PREPARATION COMPRISING VONOPRAZAN
CN110538153B (zh) * 2019-09-26 2022-04-26 扬子江药业集团四川海蓉药业有限公司 一种高稳定性、快速释放的固体制剂及其制备方法
UY39094A (es) * 2020-02-27 2021-07-30 Hk Inno N Corp Composición farmacéutica que comprende compuesto derivado de bencimidazol
EP4271365A1 (en) * 2020-12-30 2023-11-08 HK inno.N Corporation Pharmaceutical composition comprising tegoprazan and non-steroidal anti-inflammatory drugs
KR102648314B1 (ko) 2021-12-08 2024-03-15 (주) 팜젠사이언스 벤즈이미다졸 유도체 화합물 및 이의 용도

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9600070D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
GB9814215D0 (en) 1998-07-01 1998-09-02 Norton Healthcare Ltd Anti-inflammatory pharmaceutical formulations
US20020028240A1 (en) * 2000-04-17 2002-03-07 Toyohiro Sawada Timed-release compression-coated solid composition for oral administration
US6544556B1 (en) 2000-09-11 2003-04-08 Andrx Corporation Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor
US8206741B2 (en) * 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
MXPA03011017A (es) 2001-06-01 2005-04-29 Pozen Inc Composiciones farmaceuticas para la entrega coordinada de nsaids.
DE10317023A1 (de) 2003-04-11 2004-11-11 Altana Pharma Ag Perorale Arzneimittelzubereitung für Protonenpumpenantagonisten
TW200503783A (en) 2003-04-11 2005-02-01 Altana Pharma Ag Oral pharmaceutical preparation for proton pump antagonists
SA04250092B1 (ar) 2003-05-14 2008-05-04 التانا فاروا ايه جي مركب وسيط جديد لتحضير مركبات إيميدازوبيريدين imidazopyridines فعالة علاجياً
AU2004285394B2 (en) 2003-11-03 2009-01-08 Astrazeneca Ab Imidazo (1,2-A) pyridine derivatives for the treatment of silent gastro-esophageal reflux
EP1718303A4 (en) 2004-02-10 2010-09-01 Santarus Inc COMBINATION OF INHIBITOR OF PROTON PUMP, BUFFER AND NON-STEROIDAL ANTI-INFLAMMATORY DRUG
CA2558027A1 (en) * 2004-03-03 2005-09-15 Spherics, Inc. Polymeric drug delivery system for hydrophobic drugs
AR057181A1 (es) 2005-11-30 2007-11-21 Astra Ab Nueva forma de dosificacion de combinacion
US7776873B2 (en) 2005-12-01 2010-08-17 Yuhan Corporation Method for treating damage to gastric mucosa
WO2007125397A2 (en) 2006-04-27 2007-11-08 Vecta, Ltd. Compositions and methods for inhibiting gastric acidity using endoperoxide bridge-containing compounds
US20090131386A1 (en) 2007-11-13 2009-05-21 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
BRPI0916689A2 (pt) 2008-07-28 2015-11-17 Takeda Pharmaceutical composição farmacêutica estabilizada, preparação sólida, e, métodos para estabilizar uma composição farmacêutica, e para estabilizar uma preparação sólida.
CN102197033B (zh) 2008-08-27 2014-07-16 武田药品工业株式会社 吡咯化合物
US20100305163A1 (en) * 2009-05-20 2010-12-02 Pramod Dattatray Yedurkar Pharmaceutical formulations comprising nsaid and proton pump inhibitor drugs
US20110097401A1 (en) 2009-06-12 2011-04-28 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
CA2797809A1 (en) 2010-04-30 2011-11-03 Takeda Pharmaceutical Company Limited Enteric tablet
JP5787882B2 (ja) 2010-04-30 2015-09-30 武田薬品工業株式会社 腸溶性錠剤
UY34478A (es) 2011-11-30 2013-06-28 Takeda Pharmaceutical Comprimido recubierto seco
BR112014016085A8 (pt) 2011-12-28 2017-07-04 Pozen Inc composições aprimoradas e métodos para distribuição de omeprazol mais ácido acetilsalicílico
CN105412038A (zh) * 2015-12-11 2016-03-23 北京阜康仁生物制药科技有限公司 一种包含沃诺拉赞和非甾体抗炎药的复方制剂

Also Published As

Publication number Publication date
SG10201914087UA (en) 2020-03-30
CN108135915A (zh) 2018-06-08
BR112018001859B1 (pt) 2023-05-02
EP3329921A4 (en) 2019-03-27
MX2018001209A (es) 2018-07-06
EP3329921B1 (en) 2024-03-27
KR20180030412A (ko) 2018-03-22
EP3329921A1 (en) 2018-06-06
CO2018000991A2 (es) 2018-05-10
BR112018001859A2 (pt) 2018-11-27
JP6778680B2 (ja) 2020-11-04
CL2018000246A1 (es) 2018-06-29
JPWO2017018473A1 (ja) 2018-05-17
PH12018500236A1 (en) 2018-08-13
WO2017018473A1 (ja) 2017-02-02
US20180214460A1 (en) 2018-08-02
PE20180605A1 (es) 2018-04-09
CR20180119A (es) 2018-03-21
ECSP18015616A (es) 2018-07-31
CN108135915B (zh) 2021-06-25
SG11201800591TA (en) 2018-02-27
CA2994073A1 (en) 2017-02-02
TWI710379B (zh) 2020-11-21
US10835541B2 (en) 2020-11-17
TW201714608A (zh) 2017-05-01
MY189306A (en) 2022-02-03
CA2994073C (en) 2023-09-05

Similar Documents

Publication Publication Date Title
GB201707959D0 (en) No details
DK3256579T3 (en) Cysteinprotease
DK3256580T3 (en) Cysteinprotease
AU356804S (en) Tablet
DK3250592T3 (en) Anti-transthyretin-antistoffer
GB201706130D0 (en) No details
GB201612542D0 (en) no details
GB201615071D0 (en) No details
IL254818A0 (en) Ribociclib tablet
HK1249857A1 (zh) 片劑
GB201709180D0 (en) No details
DK3272750T3 (en) Morphinan-derivat
GB201420300D0 (en) Tablet
AU361999S (en) Ballustrade
GB201616225D0 (en) No details
DK3133099T3 (en) Polymermodificeret polyoldispersion
DK3282866T3 (en) Proteinfibre
DK3250312T3 (en) Urea-metalnitrat-scr-system
GB201708207D0 (en) No details
GB201702336D0 (en) No details
AU356801S (en) Tablet
EP3431079C0 (en) COMPRESSED
DK3242882T3 (en) Cgrp-antagonistpeptider
GB201511252D0 (en) Tablet
TWM532873U (en) Tablet structure